Objective: To compare the efficacy, safety, and recurrence rates of topical salicylic acid/lactic acid (SA/LA) monotherapy (Group A), intralesional Candida antigen (CA) monotherapy (Group B), and their combination (Group C) for the treatment of warts.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
126
Patients receive topical application of Salicylic Acid 40% and Lactic Acid 16% once daily for up to 6 weeks.
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions.
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions, with topical Salicylic Acid 40% and Lactic Acid 16% applied in between.
Outpatient Clinic of Dermatology, Venereology and Andrology Department at Benha University Hospitals
Banhā, Qalyubia Governorate, Egypt
Complete Response (CR) Rate
Percentage of patients achieving complete disappearance of all warts.
Time frame: 3 months post-treatment
Distant Wart Clearance Rate
Percentage of patients achieving clearance of non-injected/distant warts.
Time frame: 3 months post-treatment
Recurrence Rate
Percentage of patients with recurrence of warts after achieving CR.
Time frame: 6 months post-treatment
Safety and Tolerability Profile
Incidence and severity of local (pain, edema, crustations) and systemic (flu-like symptoms) side effects.
Time frame: At each visit (every 2 weeks) and 3 months post-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.